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ABSTRACT
Objectives: To develop and validate the constipation treatment
satisfaction questionnaire (CTSAT-Q) for use in patients with chronic
constipation and irritable bowel syndrome with constipation (IBS-c).
Methods: Questionnaire development included item representation from
the reviewed literature, focus groups, and pretesting. Dimensions related
to treatment satisfaction were identiﬁed with exploratory factor analysis,
veriﬁed with conﬁrmatory factor analysis (CFA), and tested with structural
equation modeling.
Results: A total of 31,988 email invitations were disseminated to obtain
311 qualiﬁed respondents with diagnoses for chronic constipation and
IBS-c using ROME II criteria, which required that two of the following
symptoms: fewer than 3 bowel movements per week, hard or lumpy
stools, straining with defecation, and a sensation of incomplete evacua-
tion, a sensation of anorectal obstruction, and the use of manual maneu-
vers to assist defecation be present 25% of the time during the last year.
Approximately 84% of the sample was female. Item-to-total correlations
were 0.66 for activities, ranged from 0.60 to 0.67 for expectations, from
0.59 to 0.69 for value, from 0.56 to 0.60 for effectiveness, and 0.68 to
0.79 for treatment satisfaction. All standardized parameter estimates
from CFA were signiﬁcant (P < 0.01). The chi-square was 46.98, df =
41, P = 0.241, comparative ﬁt index = 0.996, Tucker-Lewis Index =
0.994, root mean square error of approximation = 0.022, indicating an
excellent ﬁt between the sample data and proposed model. Treatment
satisfaction was a strong and signiﬁcant predictor of effectiveness, activi-
ties, and value (P < 0.001).
Conclusions: The CTSAT-Q was demonstrated to be reliable and valid,
and appears to assess treatment satisfaction for patients with chronic
constipation and patients with IBS-c.
Keywords: chronic constipation, instrument development, irritable bowel
syndrome, treatment satisfaction.
Background
The prevalence of chronic constipation ranges from 12% to 19%
and is characterized by infrequent bowel movements (<3 per
week) lasting more than 3 months and typically for many years
[1]. Although chronic constipation and irritable bowel syndrome
with constipation (IBS-c) share many symptoms in common (e.g.,
straining, hard or lumpy stools, sensation of incomplete evacu-
ation), the presence of abdominal discomfort is likely to label a
patient as having IBS-c rather than having chronic constipation
alone [2]. Chronic constipation is not typically life threatening;
however, patients are likely to experience some level of frustra-
tion resulting from uncertain and unexpected outcomes from
medication use, modiﬁcation in diet, and exercise, all which may
or may not be successful. In fact, numerous research articles have
described the bothersome effects of chronic constipation and
how symptoms inﬂuence quality of life [3,4] and productivity [5],
and impose a burden on health-care resources [6]. Chronic con-
stipation is a long-term condition that dominates both physi-
ological and psychological aspects of the individual.
Studies describing the adverse effects of chronic constipation
on patient quality of life focus on physical functioning, social
activities, and vitality [7,8]. Although the assessment of treat-
ment satisfaction in other chronic conditions [9,10] may serve as
a heuristic for chronic constipation studies, treatment satisfac-
tion remains somewhat elusive because patients with chronic
constipation realize that full recovery is questionable and what
constitutes acceptable treatment may not equate with desired
outcomes. For example, in a recent study, as many as 47% of the
respondents were reportedly dissatisﬁed with their current treat-
ment. Dissatisfaction was attributed to the inability of medi-
cations to control or provide symptom relief and the lack of
predictability [11]. Given that patients with chronic constipation
and IBS-c share similarities in rates of prevalence, predomi-
nance for females, and impact on health-related quality of life
(HRQOL) [12], it is important to understand how treatment
satisfaction is characterized by these patients and how treatment
satisfaction relates to other dimensions considered by patients.
To address this need, we present the development and validation
of the chronic constipation treatment satisfaction questionnaire
(CTSAT-Q).
Methods
Questionnaire Development
Content validity. Items generated for use in this study were
gleaned from an extensive search through MEDLINE, sociology,
clinical, and the Internet-based literature. Items considered for
inclusion were related to treatment satisfaction and represented
a domain of treatment outcomes that would be important to
patients with constipation.
An expert panel was recruited to assess the items for content
validity. The panel consisted of six individuals, including physi-
cians, educators, pharmacists, and researchers, who reviewed
existing information and included items appropriate for the pre-
liminary questionnaire. After revisions, this group agreed that the
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items selected were consistent with relevant literature and study
objectives.
Face validity. Two strategies were used to establish that respon-
dents were interpreting the items correctly. For the ﬁrst strategy,
a focus group consisting of eight individuals with constipation
participated in a series of interviews that lasted for more than
1 hour. Interviews were transcribed for further analysis using
NVivo 7 qualitative analysis software (QSR International, Cam-
bridge, MA) to identify recurring themes. Patients were excluded
if there was a history of abdominal surgery other than appen-
dectomy or hysterectomy. Patients were also excluded if there
were comorbid medical or psychiatric conditions that might rea-
sonably impact bowel function or the interpretation or tolerance
of symptoms. These include diabetes mellitus, poorly controlled
endocrine or metabolic disorders, chronic narcotic use or use of
other agents known to adversely affect digestive motility, and
untreated or poorly controlled psychiatric disorders. First, par-
ticipants were asked to complete the Bristol stool form scale
and to complete a constipation module to ensure that they met
the ROME II criteria. Second, participants were asked to
describe their symptoms and explain the most bothersome
aspects of their condition. Third, they were asked to describe
treatment satisfaction and what aspects of treatment they found
to be satisfying and worthwhile compared to not satisfying.
Fourth, responses were elicited about the value of medication use
and whether medication use provided value that was related to
monetary and nonmonetary aspects of treatment. Fifth, partici-
pants were asked to distinguish, if possible, between treatment
satisfaction and value. Each session was monitored, lasted 1.5
hours, and participants had the opportunity to provide addi-
tional responses to questions.
For the second strategy, the preliminary questionnaire was
pretested using 12 individuals with minimal symptoms. These
individuals reviewed the questionnaire for clarity, readability,
and applicability to the disease condition. Once changes were
incorporated from the focus groups, the same 12 individuals
plus an additional eight individuals completed the preliminary
questionnaire consisting of 43 items, demographic information,
measures of symptom severity, and open-ended questions for
comments to ensure relevance of the items to study objectives.
Descriptive measures were used to examine the items for redun-
dancy and comprehension. Modiﬁcations included changes in the
directions to help participants provide information that encom-
passed their entire treatment and medication experience. As
suggested, labels were placed on the top of the second page of the
questionnaire to help with item responses. Slight changes were
made to the wording of items to improve the interpretability with
respect to importance. After removing items that were redundant
and difﬁcult to understand, the ﬁnal questionnaire contained 31
items for evaluation.
Sample. An online panel obtained throughHarris Interactive was
invited through a password protected email invitation to complete
the questionnaire covering health-related topics. The panel con-
sisted of several million people who agreed to participate in survey
research. Panelists joined the online panel through 100 different
sources that used diverse recruitment strategies (e.g., graphical
placement, professional meetings, telephone recruitment) to
reduce selection bias. Data integrity was maintained by password
protection, reminder invitations, and the availability of selected
survey results after completion. Besides obtaining approval from
an Institutional Review Board from a large university in the
Midwest, the questionnaire was also reviewed by an ethics com-
mittee where the sample for the main study was obtained.
Respondents conﬁrmed their desire to participate in the
panel by clinking on a designated link and registering. Qualiﬁed
respondents were US citizens, 18 years of age or older, diagnosed
with digestive or gastrointestinal disorder by a physician, nurse,
or other health-care professional, diagnosed with chronic consti-
pation, and met ROME II criteria for chronic constipation. The
sample included patients with chronic constipation and a subset
of patients with constipation predominated IBS who reported
two or more symptoms for a total 12 weeks in the past year.
Information elicited from participants included a retrospective
assessment of treatment response along with general information
pertaining to health, comorbidities, demographics, and ethnicity.
All participants were required to provide a response to each of
the 31 items regarding their perceptions of the item’s relational
importance to treatment satisfaction ranging from 1 = not impor-
tant at all to 5 = extremely important.
Statistical approach. Data were analyzed using SPSS 15.0
Windows (SPSS Inc., Chicago, IL) and conﬁrmatory factor analy-
sis (CFA) and structural equation modeling (SEM) using analysis
of moment structures (AMOS) version 7.0 software and user’s
guide (James L. Arbuckle 1995–2006). First, descriptive statistics
and Student’s t tests were used to obtain summaries for demo-
graphic variables and to determine whether over-the-counter
(OTC) and prescribed medications contributed to a treatment
effect with respect to symptom severity. Second, a principal com-
ponents exploratory factor analysis (EFA), using Varimax rota-
tion to increase the interpretability of factors, was conducted to
identify which items have the strongest relationship to respective
factors. To be retained for further analysis, items had to have
acceptable loadings (0.3) on one factor and not have extensive
cross-loadings on other factors [13]. Item-to-total correlations
were examined with items having Cronbach’s alphas of 0.70 or
higher retained for scale development [14]. Discriminant validity
was acceptable if the Cronbach’s alphas (scale reliabilities) were
greater than the interscale correlations, and if the average corre-
lations between scale and nonscale items were lower than the
correlation between scale and scale items [15]. Third, after dis-
criminant validity was substantiated with items loading on their
appropriate constructs, the EFA model was further assessed for
reliability and validity using CFA. At this stage, the CFA model
was developed according to the constructs that were identiﬁed
from the EFA and assessed to determine how well the sample
data ﬁt the proposed model. Information produced from the
AMOS output provides changes or modiﬁcations that can be
made to paths connecting items to constructs, the constructs
themselves, and to paths existing among the measurement error
terms (e) to improve the ﬁt between the CFA model and the data
[16]. Once modiﬁcations are made as provided, various ﬁt mea-
sures are examined to assess the impact of these modiﬁcations on
the CFA model. Fit measures include chi-square, the comparative
ﬁt index (CFI: >0.90 acceptable, >0.95 excellent), the Tucker-
Lewis Index (TLI 0.90 acceptable), and root mean square error
of approximation (RMSEA) which should be0.05 to indicate a
good ﬁt between the proposed CFA model and the data [17].
Once a good ﬁt for the CFA model was established, the sample
underwent further examination for internal consistency. For the
internal cross-validation procedure, a portion (55%) of the total
sample (n = 311) was obtained using the randomization function
in SPSS 15.0 to compare the CFA model to the EFA model.
Fourth, because symptom severity was an important predictor
for chronic disease and health outcomes [18,19], it was impor-
tant to determine whether the model was applicable across
groups (i.e., participants with low compared to high symptoms).
Thus, a multigroup comparison was performed to examine the
Treatment Satisfaction 1005
factor structure across these two groups to test for model invari-
ance, that is, to examine whether the models were the same
regardless of symptom severity. A standard process for hypoth-
esis testing was used to test differences between the two groups
[17,20]. This process compared the models with factor loadings
held constant across the two groups. The process also compared
the groups with respect to factor variances and covariances as
well as the residual or measurement error variance between
groups. Finally, after acceptable levels of ﬁt and validity were
demonstrated for the CFA model, SEM was used to assess the
hypothesized relationship between the observed variables and
unobserved (latent) constructs in the proposed structural model
[21].
Results
A total of 31,988 email invitations were disseminated to patients
who met the study criteria. Of the responses, 5554 individuals
did not qualify and 207 started the process but failed to complete
the task. A total of 311 qualiﬁed respondents completed the
survey from October 10, 2007 to October 30, 2007. Approxi-
mately 84% of the sample was female with the average age of 52
(SD = 11.2; range = 24–89) years for all respondents (Table 1).
Over 80% of the sample was Caucasian and had symptoms for
about 19 years. In general, respondents were educated and
reported the use of OTC and prescribed medications to treat
symptoms of chronic constipation. Results from the paired Stu-
dent’s t test revealed that symptoms were signiﬁcantly worse
(P < 0.001) before any type of treatment compared to current
levels of symptom severity. Prescribed medications signiﬁcantly
(P = 0.002) reduced the severity of current symptoms compared
to the use of OTC medications. Results from an independent
Student’s t test revealed no differences with respect to symptom
severity (mean = 6.7; SD = 2.0) between patients with chronic
constipation and patients with IBS-c.
Factor Analysis
Data reduction using EFA with Varimax rotation produced ﬁve
dimensions that were supported by an examination of item-to-
total correlations as well as item distributional properties, such
as the mean, variance, and P-value. Item-to-total correlations
were 0.66 for activities, ranged from 0.60 to 0.67 for expec-
tations, from 0.59 to 0.69 for value, from 0.56 to 0.60 for
effectiveness, and 0.68 to 0.79 for treatment satisfaction. Item-
to-total correlations revealed that these items were consistent
measures of their proposed constructs and could be retained for
scale development. The ﬁve dimensions accounted for 73.8% of
the cumulative variance.
The exploratory factor structure was further veriﬁed by
reanalysis of the reliabilities for each of the ﬁve dimensions. Items
were eliminated if the item-to-total correlation improved once
the item was removed. Factor loadings, descriptive statistics, and
Cronbach’s alphas for each of the scales are presented in Table 2.
Cronbach’s alpha for all the 14 items was 0.91, indicating a high
signal-to-noise ratio (i.e., error variance minimized) across
respondents. Redundant items (highly intercorrelated), items
with low communalities (<0.4), and items not identiﬁable with
primarily one dimension were removed. Some of these items
included using alternative medicines, nonmedical strategies
worked best, current treatment provides adequate symptom
relief, easy to adjust the dosing schedule, medication free from
unpleasant side effects, easy to adjust the dose, medication has
reduced worry, medication use is tolerable, medication has pro-
duced the desired effect, medication has an overall pleasing
effect, medications help me feel normal, recommend medication
to others, better control over body functions, digestive system
has returned to normal.
CFA
CFA was used to assess the unidimensionality of each scale
simultaneously [22]. Unidimensionality is important to establish
that one construct underlies a set of items and that each item
should represent one and only one latent construct [23]. The
diagram in Figure 1 describes the relationship between the
observed variables (represented by boxes) and the latent con-
structs (represented by circles). The arrows connecting the latent
constructs to the items represent the loading estimates, similar to
regression coefﬁcients. The lines going into the items represent
Table 1 Sample characteristics (n = 311)*
Characteristic Value
Sex (% female) 83.9
Age (mean years, SD) 51.6 (11.4)
Symptoms for how long? (mean years, SD) 19 (16.4)
Comorbidities (% yes)
IBS 54.7
Spastic colon 16.1
Ethnicity (%)
Caucasian 81.3
Asian or Paciﬁc Islander 10.9
African American 3.5
Hispanic 0.6
Some college or better (%) 51.5
Pretreatment symptoms severity (mean, SD)† 8.8 (1.3)
Current symptom severity (mean, SD) 6.7 (2.0)
OTC medication (% yes) 69.8
Prescribed medication (% yes) 34.4
*All patients sampled met ROME II criteria for chronic constipation,which required that two
of the following symptoms: fewer than 3 bowel movements per week, hard or lumpy stools,
straining with defecation, and a sensation of incomplete evacuation, a sensation of anorectal
obstruction, and the use of manual maneuvers to assist defecation be present 25% of the time
during the last year.
†Scale: 1 = not severe at all; 10 = extremely severe.
IBS, irritable bowel syndrome; OTC, over the counter.
Table 2 Exploratory factor solution for 14 items representing treat-
ment satisfaction for patients with chronic constipation*
Item† Loading
Mean
(SD)
Expectations, alpha = 0.79
U1 leaning more about medication improves
expectations
0.85 3.7 (1.1)
U2 peace of mind 0.73 4.1 (1.0)
U3 learning more about medication has
long-term beneﬁts
0.71 4.0 (1.0)
Value, alpha = 0.79
V1 medication will have lasting beneﬁts 0.81 4.4 (0.8)
V2 medication use will have long-term beneﬁts 0.79 4.2 (1.0)
V3 medication use has future value 0.62 4.1 (1.0)
Treatment satisfaction, alpha = 0.79
S1 relief from symptoms 0.76 4.7 (0.6)
S2 expectations of medication use were met 0.73 4.3 (0.8)
S3 treatment with medication is successful 0.56 4.6 (0.7)
Activities, alpha = 0.80
A1 treatment does not interfere with social activities 0.85 4.2 (1.0)
A2 medication does not interfere with daily activities 0.82 4.4 (0.9)
Effectiveness, alpha = 0.75
C1 able to continue medication use 0.76 4.3 (0.9)
C2 ability of medication to control symptoms 0.69 4.5 (0.8)
C3 medication is safe for long-term use 0.63 4.6 (0.7)
*Cronbach’s alpha = 0.91; total explained variance = 73.8% using Varimax rotation.
†Scale: 1 = not important at all; 5 = extremely important.
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an error term (e) to be interpreted as measurement error for the
observed variables. The curved lines connecting the latent con-
structs represent the correlation between these latent constructs
in the measurement model, which should be allowed to correlate
[23].
CFA revealed a good ﬁt of model: c2 = 46.98, df = 41,
P = 0.241, CFI = 0.996, TLI = 0.994, RMSEA = 0.022, with all
parameters signiﬁcant. The curved lines connecting the error
terms (e) in the measurement model represent a signiﬁcant cor-
relation (P < 0.01) between the error terms (e), and indicate the
extent that measurement error is associated with the observed
variables. Throughout the two-stage approach, where the mea-
surement model is developed before the structural model, corre-
lation between the error terms (e) is justiﬁed when improvements
in model ﬁt are signiﬁcant. The average variance extracted (AVE)
can be used to assess discriminant validity, where the AVE for
each construct should be greater than the squared correlation
between the constructs and any other construct [24]. The AVE
for this study ranged from 0.73 to 0.81 and the squared corre-
lations ranged from 0.30 to 0.53, with one correlation between
effectiveness and treatment satisfaction (r = 0.74) exceeding the
AVE for effectiveness. No residuals associated with the measure-
ment of items were greater than 2.0, and the largest positive
residual was 1.39 and the largest negative residual was -1.26.
Although the correlation between effectiveness and treatment
satisfaction was high (0.86), constraining this relationship equal
to 1.0 provided estimates that indicated a signiﬁcantly worse ﬁt.
For the CFA model developed for cross-validation on 171
participants representing 55% of the total sample, modiﬁcation
indices were examined to determine which if any paths should be
modiﬁed or if items may be dropped to yield a more parsimoni-
ous model. Modiﬁcation indices suggested a better model ﬁt if
the items “able to continue medication” and “medication use
has future value” were removed. The goodness-of-ﬁt measures
for the ﬁnal internally cross-validated measurement model
were c2 = 42.2, df = 42, P = 0.46, CFI = 1.00, TLI = 1.00,
RMSEA = 0.005, yielding an excellent ﬁt with the sample data
(Fig. 1).
Multigroup Analysis
For multigroup analysis, the covariance matrices for two groups
were compared for differences. If one group with low symptom
severity and the other group with high symptom severity were
completely different, the covariance matrices would be different.
Results presented in Table 3 revealed that differences between the
two models with factor loadings constrained to be equal between
the two groups yielded a nonsigniﬁcant chi-square difference
(c2 = 7, df = 7, P = 0.676). Model invariance at this stage indi-
cates that the ﬁve dimensions (activities, expectations, value,
effectiveness, and treatment satisfaction) appear to be applicable
to both groups. After continued testing at subsequent levels,
however, invariance between the two groups was no longer
supported.
To explore the possibility that there was a moderating effect
at the structural level, the model was reassessed to determine
where group differences were most pronounced. When the item
“treatment with medication is successful” was moved from the
construct representing treatment satisfaction to the construct
representing effectiveness for respondents with lower symptom
severity, the chi-square difference was c2 = 15, df = 22, P =
0.025. Other differences between groups were primarily attrib-
uted to differences resulting from the measurement residuals.
Nevertheless, the goodness-of-ﬁt measures did not decline sub-
stantially and were not likely inﬂuenced by sample size.
Modeling Process
SEM was used to test the causal relationships in the proposed
conﬁrmatory model. The ﬁnal structural equation model using
the entire sample was produced when the items “able to continue
medication” and “medication use has future value” were
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Figure 1 Conﬁrmatory factor analysis model for dimensions relating to treat-
ment satisfaction for patients with chronic constipation.
Table 3 Model derivation from conﬁrmatory factor analysis and multigroup comparison
Model assessment Chi-square df P TLI CFI RMSEA
Conﬁrmatory factor model (cross-validation) (n = 171)
Removed item “able to continue medication” 58.4 53 0.283 0.952 0.995 0.025
Removed item “medication has future health value” 42.2 42 0.462 1 1 0.005
Test for structural invariance using multigroup comparison factor analysis
(low symptoms; n = 132 : high symptoms; n = 179)
Unconstrained—no restrictions on parameters for both models 68 88 0.001 0.957 0.971 0.042
Constrained—factor loadings restricted to be equal for both models 61 95 0.001 0.962 0.973 0.04
Dc2 Ddf P DTLI DCFI DRMSEA
Factor loadings change in value 7 7 0.676 0.005 0.002 0.002
CFI, comparative ﬁt index; RMSEA, root mean square error of approximation;TLI.Tucker-Lewis index.
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removed. All standardized parameter estimates were signiﬁcant
(P < 0.01), indicating that the sample data support the proposed
conceptual model presented in Figure 2. The chi-square was
57.56 (df = 46), P = 0.118, CFI = 0.993, TLI = 0.990, RMSEA =
0.028. All goodness-of-ﬁt measures supported an excellent ﬁt
between the data and the proposed model [25].
The model presents the standardized estimates, which were
useful for assessing the hypothesized relationship among the
latent constructs. In this model, participant expectations of
chronic constipation had a positive and signiﬁcant impact on
treatment satisfaction and value had moderate signiﬁcant
effect on expectations. Treatment satisfaction was a signiﬁcantly
important predictor of value, activities, and effectiveness of
therapy. In the ﬁnal model, the item “treatment with medication
is successful” remained with the treatment satisfaction construct.
A slight but signiﬁcant negative correlation (P = 0.014) was
noted between the error terms (e) associated with the observed
variables used to measure expectations “learning more about
medication has long-term beneﬁts” and treatment satisfaction
“relief from symptoms.” The error terms (e) associated with the
other two observed variables measuring treatment satisfaction
(expectations of medication use were met, and treatment with
medication is successful) were signiﬁcantly correlated (P < 0.01)
with the disturbance term (z3) associated with the latent factor
effectiveness, where z represents the residual error or disturbance
in the prediction of the latent (unobserved) factor. Although
a very strong relationship between treatment satisfaction and
effectiveness of therapy was noted (coefﬁcient = 0.91), a more
parsimonious model consisting of four constructs, combining
treatment satisfaction with effectiveness, was not supported.
Discussion
The overall objective of this study was to develop the chronic
CTSAT-Q. Questionnaire development followed a standard and
rigorous process, which included item generation, exploratory
and CFA, and SEM. This approach is well recognized and of
paramount importance to the research and development
process when establishing the usefulness of new questionnaires
in the area of outcomes research. Results reported here repre-
sent the ﬁrst opportunity to develop a questionnaire to address
treatment satisfaction for patients with chronic constipation
and IBS-c.
With the exception of pain and abdominal discomfort, few
differences are known to exist between patients with chronic
constipation and IBS-c. Nevertheless, because the sample con-
tained both groups, an examination of participants with respect
to symptom severity in the cross-validation part of the study was
necessary to determine whether patient perceptions were similar
for each measurement model. If differences existed, it was im-
portant to ascertain whether differences were attributed to the
patient population per se or perhaps attributed to differences in
perceptions. As revealed, similar dimensions were identiﬁed for
patients with low and high symptoms. Moreover, a separate SEM
including only IBS-c participants produced an equivalent model,
that is, the dimensions and the relationship among the dimen-
sions were the same for both groups. Further examination of
the loadings revealed that one item, “treatment with medication
was successful,” aligned more with the construct effectiveness for
participants with low symptom severity. Nevertheless, the strong
relationship between treatment satisfaction and effectiveness of
therapy may account for subtle nuances in the way these items
loaded on their respective dimensions. Similar patterns were also
observed when analysis of variance was used to compare partici-
pants with chronic constipation and IBS-c participants across
the ﬁve dimensions. With the exception that IBS-c participants
wanted a greater understanding of their condition compared to
chronic constipation participants (P < 0.008), there were no sig-
niﬁcant differences between the groups. The ﬁnding that IBS-c
participants are knowledgeable about treatment options and in
general expect more information about their condition is also
supported in the literature [26,27]. Although the sample of par-
ticipants examined in this study may impart other biases through
individual differences that could not be measured, this instru-
ment appears to be useful in patients with either chronic consti-
pation or patients with IBS-c.
Theoretical support for our model is documented in the
literature from other studies that examined the impact of symp-
toms and symptom severity with respect to treatment satisfac-
tion. For example, treatment satisfaction for patients with low
back pain was assessed using three measures, two of which
assessed treatment delivery: “consider the same treatment again
for the same condition,” “rating of overall results from treat-
ment,” and one item, “how would the patient feel about spend-
ing the rest of their life with their current level of symptoms,” to
assess treatment effect [28]. Results revealed that patient satis-
faction was high for items related to treatment delivery and low
for items related to treatment effect [29]. In this study, perhaps,
respondents with low symptom severity associated the item
“treatment with medication is successful” as a measure of
treatment delivery and respondents with high symptom severity
associated this measure with treatment effect. In another study
examining treatment satisfaction for gastroesophageal reﬂux
disease, treatment satisfaction was highly correlated with other
outcome measures such as HRQOL [29]. It was also noted that
patients had difﬁculty distinguishing between treatment satisfac-
tion and symptom relief, which was also apparent in this study
as the item “relief from symptoms” loaded highly on treatment
satisfaction. Studies in the area of overactive bladder report that
patient satisfaction with treatment was best correlated with two
scales that deﬁne the component “bother,” whereas correlations
with traditional symptoms (urgency, frequency) were weaker
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Figure 2 Structural equation model of dimensions relating to treatment sat-
isfaction for patients with chronic constipation.
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[30]. Again, these ﬁndings support the need to further examine
the relationship between the physical attributes associated with
chronic constipation and the underlying psychological structure
that drives treatment satisfaction, especially the relationship that
appears to exist between treatment satisfaction and HRQOL.
Chronic constipation for the most part is not life threatening,
yet the symptoms have a substantial impact on patient percep-
tions of their disease and, perhaps, their response to treatment
and the value of treatment. In this study, the relationship between
treatment satisfaction and value was positive. To our knowledge,
this is one of the ﬁrst studies to capture the relationship between
treatment satisfaction and value perceived as long-term beneﬁts.
Interestingly, in this study, the traditional approach used to assess
value from a monetary standpoint “getting my monies worth
from medication use” was not a signiﬁcant predictor [31]. Given
that newer treatments for chronic constipation offer more predi-
cable and palliative solutions to symptom management, perhaps
a long-term commitment to medication use by patients is more
likely to exert a positive effect on treatment value. This ﬁnding is
an important consideration for product development in chronic
disease areas where treatment efﬁcacy may be more difﬁcult to
establish [32].
Although the relationship between treatment satisfaction
and effectiveness was high, a more parsimonious model was
not acceptable; thus, the existence of two distinct dimensions
was supported. Previous studies also revealed that satisfaction
with treatment was associated with a desire to continue therapy
[33,34]. Despite the high factor loading of the item “able to
continue medication” in the EFA, the item was removed from the
ﬁnal model to produce a more parsimonious model with better
ﬁt. The relationship between effectiveness and treatment satisfac-
tion may be more complex than originally proposed in this study
as effectiveness was supported by two items relating to symptom
control and safety. Also noteworthy is that the negative correla-
tion between the item “learning more about medication has
long-term beneﬁts” and the item “relief from symptoms” sug-
gests that within the scope of this study, a temporal relationship
may exist between expectations and treatment satisfaction. Nev-
ertheless, treatment satisfaction continues to serve as a bench-
mark to assess health outcomes that patients deem important to
their well-being. Clearly, future research is needed to disentangle
the relationship between symptom severity, effectiveness of
therapy, and treatment satisfaction. Additional studies are
needed to examine how the CTSAT-Q performs across subjects
recruited from different environments (e.g., family practice, sec-
ondary care clinics, and from referrals), and further work will be
needed to generalize such ﬁndings to constipation sufferers.
Although our model ﬁt was excellent, this area of research
appears to be rife with conceptual and theoretical challenges.
Conclusion
In this study, a new questionnaire was developed to assess treat-
ment satisfaction for patients with chronic constipation (CTSAT-
Q). Acceptable measures were obtained for reliability and validity
using exploratory and CFA followed by SEM. The CTSAT-Q can
be used as a research tool to understand the relationship between
treatment satisfaction and effectiveness of therapy in clinical
studies and treatment value as health-care resources are channeled
to improve health-related outcomes in patient care.
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